BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the expansion of its product portfolio with the addition of the BD Innova™ Preanalytical Automated Microbiology Specimen Processor, which is designed to help increase laboratory efficiency and automate the modern microbiology laboratory.

By acquiring the Lab Systems division of Dynacon, a privately held corporation based in Ontario, Canada, BD adds innovative product platforms from a leader in preanalytical microbiology automation.  These product platforms include the innovative InocuLAB and Innova platforms.

"Today's clinical microbiology laboratories face many challenges; chief among them are a shortage of laboratory professionals and an increase in workload," said Philippe Jacon, President, Diagnostic Systems, BD.  "The addition of Dynacon's Lab Systems portfolio demonstrates BD's commitment to providing labs with the tools and products they need to enhance the quality of their tests results, improve turnaround times and make the most cost-effective use of their resources."

Clinical laboratories throughout North America and Europe have used the InocuLAB system routinely for nine years to successfully process more than 42 million specimens.  The recently launched Innova System, a versatile, state-of-the-art, high-throughput specimen processor, helps address laboratories' increasing needs for preanalytical specimen processing automation due to labor shortages or increasing test volumes.  It also helps reduce laboratory errors associated with specimen handling.  With best-in-class flexibility, the BD Innova System accommodates the full range of microbiology specimen containers, streak patterns, protocols and workflows.

"The features and benefits of Dynacon's Innova and InocuLAB platforms complement perfectly the capabilities of BD's innovative product portfolio," said Dr. Peter Hughes, Chairman, Director and Chief Executive Officer, Dynacon.  "As a leader in infectious disease testing known for quality and reliability, BD is the right company to bring these successful platforms to more laboratories that need and demand reliable, high-performance, automated instruments."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BD (Becton, Dickinson and Company). (2019, June 19). BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20100407/BD-Diagnostics-adds-Innova-Preanalytical-Automated-Microbiology-Specimen-Processor-to-product-portfolio.aspx.

  • MLA

    BD (Becton, Dickinson and Company). "BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20100407/BD-Diagnostics-adds-Innova-Preanalytical-Automated-Microbiology-Specimen-Processor-to-product-portfolio.aspx>.

  • Chicago

    BD (Becton, Dickinson and Company). "BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio". News-Medical. https://www.news-medical.net/news/20100407/BD-Diagnostics-adds-Innova-Preanalytical-Automated-Microbiology-Specimen-Processor-to-product-portfolio.aspx. (accessed November 21, 2024).

  • Harvard

    BD (Becton, Dickinson and Company). 2019. BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20100407/BD-Diagnostics-adds-Innova-Preanalytical-Automated-Microbiology-Specimen-Processor-to-product-portfolio.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
BD reports adjusted revenues of $3.133 billion for third fiscal quarter 2015